Skip to main content
Defiance International

Published study records

Study records.

Identifier-confirmed and citation-only records have not passed evidence or citation verification. These checks do not establish evidence strength, efficacy, safety, or suitability.

Read each study in its experimental context. A shared molecule name or database link does not establish that our material matches a study's formulation, composition or preparation. Study findings are not measurements of our inventory, promises of a biological result or authorization to use our materials in humans or animals. Actual Product specifications and lot reports are separate records.

Study record counts

68,366 study records.

407 evidence-verified · 10,493 citation-verified · 57,416 identifier-confirmed · 50 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • Human research: 689
  • In vitro: 2,868
  • In vivo/preclinical: 3,719
  • Review/meta-analysis: 3,624
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type: In vivo/preclinical · Verification: Citation only

  • 2025

Synergistic Effects of Cerebrolysin and Aerobic Exercise on 6-hydroxydopamine-induced Model of Parkinson Disease in Adult Male Rats

Basic and Clinical Neuroscience Journal · 2025

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Citation only

  • 2025

Expression of the Serum MOTS-c and Its Correlation with Atrial Remodeling in Patients with Atrial Fibrillation

DOAJ (DOAJ: Directory of Open Access Journals) · 2025

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Human research · Verification: Citation only

  • 2025

Neuroprotective Effects of Cerebrolysin in Moderate Traumatic Brain Injury with Nonoperative Lesions: A 6-Month Prospective Cohort Analysis

Asian Journal of Neurosurgery · 2025

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Citation only

  • 2023

BPC-157 Dosage: Understanding the Basics for Optimal Results

Zenodo (CERN European Organization for Nuclear Research) · 2023

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation only

  • 2022

Pentadecapeptide BPC 157 Anti‐Ulcer Effect After Stomach Perforation also Opposed the Intracranial Hypertension (Superior Sagittal Sinus), Portal and Caval Hypertension and Aortal Hypotension

The FASEB Journal · 2022

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation only

  • 2022

Pentadecapeptide BPC 157 Counteracts Hemodynamic and ECG Disturbances Induced by Sotalol in Rats

The FASEB Journal · 2022

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation only

  • 2022

MOTS‐c protein expression increases following aerobic exercise training and remains elevated during detraining

The FASEB Journal · 2022

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation only

  • 2022

FTIR Spectroscopy Reveals Molecular Changes in BPC 157 Treated Blood Vessels

The FASEB Journal · 2022

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation only

  • 2021

Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice

UNC Libraries · 2021

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Citation only

  • 2021

Novelties regarding pentadecapeptide BPC-157

Zenodo (CERN European Organization for Nuclear Research) · 2021

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Citation only

  • 2020

China péptido de suministro de Mt -II 10 mg/vial con la construcción de músculo de la USP Melanotan II una experiencia de laboratorio en energías renovables

2020

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation only

  • 2020

The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice

UNC Libraries · 2020

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.